Evaluation of sputum MMP9 in COPD subject, version1
Research type
Research Study
Full title
A Translational Multicenter Study to Evaluate Sputum MMP9 Levels and Enzyme Activity in Subjects with Chronic Obstructive Pulmonary Disease(COPD) Compared to Matched Healthy Controls
IRAS ID
186542
Contact name
Chris Brightling
Contact email
Sponsor organisation
Gilead
Clinicaltrials.gov Identifier
2015-001996-21, EudraCT
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
The purpose of this study is to measure the amount of MMP9, in the lungs. MMP9 is a protein that may breakdown other important proteins in the lung. High levels of MMP9 in the lung may be related to more severe COPD lung disease.
There is no experimental drug in this study.
About 80 participants from approximately 10 sites worldwide will be recruited into this study. Approximately 30 participants will be recruited in the UK.
Participation in this study for a subject will involve one main study visit, followed by an optional visit between 4-14 days after the first. Both visits can be either performed on one day or spread across two. There will therefore be a total of up to 4 visits per patient, occurring over a timeframe of 1-14 days.
The procedures are : medical history, physical examination, vital signs, urine tests, blood tests, and sputum induction and lung function tests.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
15/EM/0351
Date of REC Opinion
20 Aug 2015
REC opinion
Further Information Favourable Opinion